Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of carbidopa/levodopa enteral suspension in patients with advanced Parkinson's Disease:PROviDE study

Next Previous
Search
Trial Profile

Efficacy of carbidopa/levodopa enteral suspension in patients with advanced Parkinson's Disease:PROviDE study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PROviDE

    • Most Recent Events

    • 29 Oct 2021 According to an Abbvie media release, data from this study were presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021
    • 10 Sep 2021 According to an Abbvie media release, data from this study will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22
    • 22 Apr 2021 Interim Results (n=38) from the PROviDE Study, presented at the 73rd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top